Trial Profile
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 25 Dec 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Pembrolizumab (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Focus Adverse reactions
- 20 Dec 2023 Planned number of patients changed from 40 to 21.
- 01 Sep 2023 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 01 Sep 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2025.